IRWD 241220 12.50P (IRWD241220P12500) Stock Options, News & Quotes

US OptionsDetailed Quotes

IRWD241220P12500

Watchlist

4.96
0.000.00%

15min DelayClose Dec 13 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Ironwood Pharmaceuticals On Pace for Largest Percent Increase Since January 2014 -- Data Talk
Dow JonesDec 9 13:43 ET
Beam Therapeutics Picks Ironwood Pharmaceuticals Finance and Operations Chief as CFO
Seeking AlphaDec 6 07:13 ET
Why Investors Shouldn't Be Surprised By Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) 26% Share Price Plunge
Simply Wall StDec 6 05:55 ET
Ironwood Pharmaceuticals, Inc.: Effective Dec. 18, CEO Thomas McCourt Will Serve as Principal Financial Officer on Interim Basis >IRWD
Dow JonesDec 5 17:59 ET
Express News | Ironwood Pharmaceuticals Inc - Sravan K. Emany to Resign as Svp, COO, and CFO
ReutersDec 5 17:02 ET
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
BusinesswireNov 26 16:01 ET

Comments

Meltyy

May 12 21:23

🎯 Ph 3 readouts in Q2 2024...

$United Therapeutics (UTHR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3...

Luzi Ann Santos

Feb 29 10:54

Columns Ironwood Pharma Shares Tank 40% as Drug Trial Misses Secondary Goal

$Ironwood Pharmaceuticals (IRWD.US)$ shares sank almost 40% after the drugmaker said its global phase III trial of Apraglutide, a treatment for short bowel syndrome, missed two of its four secondary goals.
That muddies the prospects for the company that's seeking to expand its product pipeline beyond Linzess.
Ironwood, which has been operating at a loss, sourced almost ll of its $117.6 million revenue in 2023 from its collaborati...

Meltyy

Feb 21 22:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer (PFE.US)$ Phase 3
$Palatin Technologies (PTN.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ $Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$...

Moomoo AI

Feb 18 08:16

Thomas McCourt's recent sale at the current share price of US$14.58 raises caution. More selling than buying by insiders over the past year and low insider ownership could concern potential investors.

Ironwood Pharmaceuticals CEO & Director Thomas McCourt Sells 39% Of Holding

Meltyy

Jan 31 14:38

Ph 3 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 3
$Regenxbio (RGNX.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Vertex Pharmaceuticals (VRTX.US)$ Phase 3
$KalVista Pharmaceuticals (KALV.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$Applied Therapeutics (APLT.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3...